| 7.14 Data as of May 17 |  -0.09 / -1.24%Today’s Change | 6.34 Today|||52-Week Range 15.96 | -11.74% Year-to-Date |
| Previous close | 7.23 |
| Today’s open | 7.36 |
| Day’s range | 7.08 - 7.39 |
| Volume | 2,621,602 |
| Average volume (3 months) | 3,686,783 |
| Market cap | $1.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -133.73% |
| Earnings growth (this year) | -56.14% |
| Earnings growth (next 5 years) | +30.70% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| NKTRNektar Therapeutics | +0.19 | +1.98% |
| LXRXLexicon Pharmaceutic... | +0.03 | +1.38% |
| EXELExelixis Inc | 0.00 | 0.00% |
| BRLIBio-Reference Labora... | +0.79 | +2.70% |
| Next reporting date | August 13, 2013 |
| EPS forecast (this quarter) | -$0.38 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$179.5M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Executive Chairman & Chief Executive Officer Joseph S. Zakrzewski, MBA |
President & Chief Financial Officer John F. Thero, CPA |
Corporate headquarters Dublin, Dublin |
.
